18F-G1 PET/CT to see early immunotherapy response in solid tumors and blood cancers
Official title: The Application of 18F-G1 PET/CT Targeting Granzyme B in the Pan-cancer Immunotherapy
Run by Peking University First Hospital · NCT07039474 · Data updated 2026-11-12
We are testing if the 18F-G1 PET/CT scan can help tell early on whether people with solid tumors or blood cancers will respond to immunotherapy.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 120 (estimated) |
| Sponsor | Peking University First Hospital Academic / other |
| Drugs / interventions | immunotherapy |
| Locations | 1 site (Beijing) |
| Status | Recruiting |
| Started | September 8, 2026 |
| Main results expected | December 1, 2028 |
| Study ends | December 15, 2028 |
| Registry record updated | September 28, 2026 |
| Trial ID | NCT07039474 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with solid tumors or hematologic cancers who are about to start immunotherapy and have at least one measurable lesion.
✕Probably not a fit
Patients who do not exhibit measurable disease changes on the scan or who do not respond to immunotherapy may not derive the predicted predictive advantage.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study will use the 18F-G1 tracer PET/CT to image patients with solid tumors or hematologic cancers who are starting immunotherapy. The aim is to characterize imaging features, assess safety, and see if the scan can predict early treatment response and prognosis. Researchers hope to aid clinicians in selecting patients, adjusting regimens, and avoiding unnecessary side effects. The study will enroll participants who meet criteria such as having measurable disease, good performance status, and the intention to receive immunotherapy as determined by a multidisciplinary team.
Why it matters
Potential benefit: If successful, the approach could help identify likely responders to immunotherapy and guide treatment decisions.
How similar studies have gone: Previous work with granzyme B–targeted imaging shows promise for assessing immunotherapy response, but broader validation is needed for widespread use.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Subjects diagnosed with a malignant tumor by histopathology who are going to receive immunotherapy (monotherapy or combined immunotherapy) recommended by the multidisciplinary team. 2. Subjects didn't receive previous immunotherapy. 3. There exists at least one measurable target lesion according to the RECIST 1.1. 4. ECOG performance status≤2. 5. The expected survival time is ≥6 months. 6. Effective contraceptive measures will be adopted during the study period and within 6 months after the study. 7. Willing and able to fully understand and sign the informed consent form. Exclusion Criteria: 1. Women in the preconception period, pregnancy, or lactation period. 2. Combined with other malignant tumor. 3. Diagnosed with autoimmune disease, or have long history of systemic steroid hormone therapy or immunosuppressive therapy. 4. Having a history of severe cardiovascular disease, severe hepatic and renal insufficiency. 5. Receiving radiotherapy or interventional therapy during the immunotherapy. 6. 18F-G1 PET/CT or 18F-FDG PET/CT is not performed in our department, or the interval between baseline imaging and immunotherapy is more than 30 days.
Where it's running
-
Peking University First Hospital
Beijing, China Recruiting
Study contacts
- Study coordinator: Caixia Wu
- Email: wucaixia314@163.com
- Phone: 010-83575252
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Using brodalumab to treat immune-related side effects from cancer therapy
This study is testing if brodalumab can help cancer patients who are having immune-related side effects from their immunotherapy treatment feel better.
-
A network for collaborative cancer research in Ontario
This study is testing a new way to improve cancer treatment by using genetics and technology to help personalize care for people with different types of cancer.
-
Validation of a blood test for early cancer detection and monitoring
This study is testing a blood test to see if it can help find different types of cancer early and monitor patients after treatment.
-
Developing a liquid biopsy protocol for cancer research at Princess Margaret
This study is trying to create a simple way to collect blood samples from cancer patients to see if analyzing certain molecules in their blood can help doctors understand their cancer better and track how it changes over time.
-
Side Effects and Resource Navigation Program for Cancer Patients
This program tests whether a navigation service helps adults with kidney, bladder, breast, or lung cancer manage immunotherapy better than usual care.
-
AI language tools to help tumor care teams write MDT reports
We will test whether AI language tools can help junior cancer doctors write MDT diagnosis and treatment reports more accurately and faster.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.